2021 Annual Meeting | Industry Therapeutic Update from Novartis Pharmaceuticals Corporation: Staying ahead of progression in RMS patients with MAYZENT® (siponimod)
Program Materials Program Evaluations
No timeline events available at this time. |
Program Materials Program Evaluations
No timeline events available at this time. |